GPS Wealth Strategies Group LLC Lowers Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

GPS Wealth Strategies Group LLC reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,172 shares of the biopharmaceutical company’s stock after selling 367 shares during the period. GPS Wealth Strategies Group LLC’s holdings in Gilead Sciences were worth $478,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. FMR LLC grew its position in shares of Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after buying an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP lifted its stake in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. Pacer Advisors Inc. grew its holdings in Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after acquiring an additional 5,653,075 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Gilead Sciences by 350.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after purchasing an additional 1,793,145 shares during the last quarter. Finally, International Assets Investment Management LLC raised its holdings in shares of Gilead Sciences by 8,238.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after purchasing an additional 1,622,806 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock worth $42,130,461 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GILD shares. UBS Group increased their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Robert W. Baird increased their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Barclays lifted their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $97.20 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The company has a market cap of $121.14 billion, a price-to-earnings ratio of 1,080.00, a price-to-earnings-growth ratio of 1.34 and a beta of 0.18. The stock has a 50 day simple moving average of $92.42 and a 200-day simple moving average of $85.87.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.